FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310736430> ?p ?o ?g. }

• W4310736430 endingPage "S1" @default.
• W4310736430 startingPage "S1" @default.
• W4310736430 abstract "Background: An initial survey (2021) examining the perceptions and attitudes of patients with inflammatory bowel diseases (IBD) relating to the COVID-19 pandemic revealed a profound impact of the pandemic on emotional and physical health. Patients experienced interruptions in routine appointments/diagnostic tests and IBD treatment. Patients also worried of increased risks of contracting COVID-19 and developing severe symptoms, leading some to discontinue medication; few, however, reported discussing these concerns with their healthcare professional (HCP). To better understand IBD patient behavior as more information and guidance about COVID19 and IBD became available, we surveyed patients one year later to reassess concerns and behaviors related to COVID-19 and vaccination. Methods: An anonymous 38-question survey was distributed to self-identified Crohn’s disease (CD) or ulcerative colitis (UC) patients, aged ≥21 years, living in the United States. The survey was accessed via the social media network MyCrohnsAndColitisTeam.com. Results: The survey was live from June 17 to July 5, 2022, and completed by 378 people (224 CD, 154 UC); most respondents were aged ≥50 years (83% CD, 83% UC) and female (75% CD, 72% UC). Most patients indicated returning to in-person activities, including HCP visits (73% CD, 71% UC), testing/procedure visits (63% CD, 64% UC), and social activities (57% CD, 62% UC), and over half reported no care disruption over the last 6 months (60% CD, 65% UC). Most reported being fully vaccinated (85% CD, 81% UC), having received at least 1 booster (71% CD, 69% UC), and were vaccinated irrespective of vaccine mandates (88% CD, 82% UC). Negative vaccine experiences were not more likely in patients with active versus inactive IBD (CD: active, 80%; inactive, 66%; UC: active, 78%; inactive, 71%). Approximately one-third of respondents reported lingering pandemic-related concerns, such as waning safety precautions (44% CD, 32% UC), the transition of COVID-19 to endemic status (39% CD, 33% UC), emergence of viral variants (39% CD, 31% UC), and duration of vaccine protection (29% CD, 29% UC). Most respondents received COVID-19 information from their HCP (58% CD, 51% UC) and mainstream media [49% CD, 40% UC]). Many reported discussing the vaccine with their HCP before/soon after vaccine approval (82% CD, 72% UC), but few respondents discussed concerns regarding receiving the vaccine while taking IBD medications (29% CD, 27% UC), spacing of IBD medications and vaccination (23% CD, 19% UC), whether vaccination could trigger a flare (23% CD, 30% UC), whether vaccination lessened medication efficacy (22% CD, 16% UC), and whether to continue IBD medications before/after vaccination (18% CD, 19% UC). Over one-third of respondents had lingering questions regarding the vaccine booster, including efficacy against variants (47% CD, 42% UC) and number of boosters needed (40% CD, 37% UC). Conclusion(s): Compared to 2021, results of the 2022 survey demonstrated changing perceptions, concerns, and behavior in IBD patients relating to the COVID-19 virus and vaccination. The high vaccination rate and confidence in returning to in-person activities are likely attributable to dissemination of medical information by HCPs and the media. However, remaining concerns, such as emergence of variants and duration of vaccine protection in a pandemic turning into an endemic situation, underscore the importance of continued communication and education between HCPs (and the scientific community) and patients." @default.
• W4310736430 created "2022-12-16" @default.
• W4310736430 creator A5051912346 @default.
• W4310736430 creator A5062392357 @default.
• W4310736430 creator A5074802047 @default.
• W4310736430 creator A5080691892 @default.
• W4310736430 creator A5081217869 @default.
• W4310736430 date "2022-12-01" @default.
• W4310736430 modified "2023-09-27" @default.
• W4310736430 title "S4 Patient Perspectives on the COVID-19 Pandemic, Its Impact on Inflammatory Bowel Disease Treatment, and Overall Well-Being One Year Later" @default.
• W4310736430 doi "https://doi.org/10.14309/01.ajg.0000897524.18646.03" @default.
• W4310736430 hasPublicationYear "2022" @default.
• W4310736430 type Work @default.
• W4310736430 citedByCount "0" @default.
• W4310736430 crossrefType "journal-article" @default.
• W4310736430 hasAuthorship W4310736430A5051912346 @default.
• W4310736430 hasAuthorship W4310736430A5062392357 @default.
• W4310736430 hasAuthorship W4310736430A5074802047 @default.
• W4310736430 hasAuthorship W4310736430A5080691892 @default.
• W4310736430 hasAuthorship W4310736430A5081217869 @default.
• W4310736430 hasBestOaLocation W43107364301 @default.
• W4310736430 hasConcept C126322002 @default.
• W4310736430 hasConcept C160735492 @default.
• W4310736430 hasConcept C162324750 @default.
• W4310736430 hasConcept C203014093 @default.
• W4310736430 hasConcept C205545832 @default.
• W4310736430 hasConcept C22070199 @default.
• W4310736430 hasConcept C2778260677 @default.
• W4310736430 hasConcept C2779134260 @default.
• W4310736430 hasConcept C2779280984 @default.
• W4310736430 hasConcept C2780479503 @default.
• W4310736430 hasConcept C3008058167 @default.
• W4310736430 hasConcept C50522688 @default.
• W4310736430 hasConcept C512399662 @default.
• W4310736430 hasConcept C524204448 @default.
• W4310736430 hasConcept C71924100 @default.
• W4310736430 hasConcept C89623803 @default.
• W4310736430 hasConceptScore W4310736430C126322002 @default.
• W4310736430 hasConceptScore W4310736430C160735492 @default.
• W4310736430 hasConceptScore W4310736430C162324750 @default.
• W4310736430 hasConceptScore W4310736430C203014093 @default.
• W4310736430 hasConceptScore W4310736430C205545832 @default.
• W4310736430 hasConceptScore W4310736430C22070199 @default.
• W4310736430 hasConceptScore W4310736430C2778260677 @default.
• W4310736430 hasConceptScore W4310736430C2779134260 @default.
• W4310736430 hasConceptScore W4310736430C2779280984 @default.
• W4310736430 hasConceptScore W4310736430C2780479503 @default.
• W4310736430 hasConceptScore W4310736430C3008058167 @default.
• W4310736430 hasConceptScore W4310736430C50522688 @default.
• W4310736430 hasConceptScore W4310736430C512399662 @default.
• W4310736430 hasConceptScore W4310736430C524204448 @default.
• W4310736430 hasConceptScore W4310736430C71924100 @default.
• W4310736430 hasConceptScore W4310736430C89623803 @default.
• W4310736430 hasIssue "1" @default.
• W4310736430 hasLocation W43107364301 @default.
• W4310736430 hasLocation W43107364302 @default.
• W4310736430 hasOpenAccess W4310736430 @default.
• W4310736430 hasPrimaryLocation W43107364301 @default.
• W4310736430 hasRelatedWork W2013349448 @default.
• W4310736430 hasRelatedWork W2037433350 @default.
• W4310736430 hasRelatedWork W2106015740 @default.
• W4310736430 hasRelatedWork W2765379856 @default.
• W4310736430 hasRelatedWork W2912638322 @default.
• W4310736430 hasRelatedWork W3022383156 @default.
• W4310736430 hasRelatedWork W3026004364 @default.
• W4310736430 hasRelatedWork W4200241788 @default.
• W4310736430 hasRelatedWork W4283657010 @default.
• W4310736430 hasRelatedWork W2065591755 @default.
• W4310736430 hasVolume "117" @default.
• W4310736430 isParatext "false" @default.
• W4310736430 isRetracted "false" @default.
• W4310736430 workType "article" @default.